Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
15 Dec 2023
15 Dec 2023
Historique:
received:
07
03
2023
accepted:
13
11
2023
medline:
16
12
2023
pubmed:
16
12
2023
entrez:
15
12
2023
Statut:
epublish
Résumé
Liver is the third most common organ for breast cancer (BC) metastasis. Two main histopathological growth patterns (HGP) exist in liver metastases (LM): desmoplastic and replacement. Although a reduced immunotherapy efficacy is reported in patients with LM, tumor-infiltrating lymphocytes (TIL) have not yet been investigated in BCLM. Here, we evaluate the distribution of the HGP and TIL in BCLM, and their association with clinicopathological variables and survival. We collect samples from surgically resected BCLM (n = 133 patients, 568 H&E sections) and post-mortem derived BCLM (n = 23 patients, 97 H&E sections). HGP is assessed as the proportion of tumor liver interface and categorized as pure-replacement ('pure r-HGP') or any-desmoplastic ('any d-HGP'). We score the TIL according to LM-specific guidelines. Associations with progression-free (PFS) and overall survival (OS) are assessed using Cox regressions. We observe a higher prevalence of 'any d-HGP' (56%) in the surgical samples and a higher prevalence of 'pure r-HGP' (83%) in the post-mortem samples. In the surgical cohort, no evidence of the association between HGP and clinicopathological characteristics is observed except with the laterality of the primary tumor (p value = 0.049) and the systemic preoperative treatment before liver surgery (p value = .039). TIL is less prevalent in 'pure r-HGP' as compared to 'any d-HGP' (p value = 0.001). 'Pure r-HGP' predicts worse PFS (HR: 2.65; CI: (1.45-4.82); p value = 0.001) and OS (HR: 3.10; CI: (1.29-7.46); p value = 0.011) in the multivariable analyses. To conclude, we demonstrate that BCLM with a 'pure r-HGP' is associated with less TIL and with the worse outcome when compared with BCLM with 'any d-HGP'. These findings suggest that HGP could be considered to refine treatment approaches.
Identifiants
pubmed: 38102162
doi: 10.1038/s41523-023-00602-6
pii: 10.1038/s41523-023-00602-6
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100Subventions
Organisme : Stichting Tegen Kanker (Belgian Foundation Against Cancer)
ID : C/2020/1441
Organisme : Stichting Tegen Kanker (Belgian Foundation Against Cancer)
ID : C/2020/1441
Organisme : Stichting Tegen Kanker (Belgian Foundation Against Cancer)
ID : C/2020/1441
Informations de copyright
© 2023. The Author(s).
Références
Wang, R. et al. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19, 1091 (2019).
Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Primers 5, 66 (2019).
Bale, R., Putzer, D. & Schullian, P. Local treatment of breast cancer liver metastasis. Cancers 11, 1341 (2019).
Rashid, N. S., Grible, J. M., Clevenger, C. V. & Harrell, J. C. Breast cancer liver metastasis: current and future treatment approaches. 38, 263–277 (2021).
Gulia, S., Khurana, S., Shet, T. & Gupta, S. Case report: radiographically occult intrasinusoidal liver metastases leading to hepatic failure in a case of breast cancer. BMJ Case Rep. 2016, bcr2015214120 (2016).
Allison, K. H., Fligner, C. L. & Parks, W. Tony. Radiographically occult, diffuse intrasinusoidal hepatic metastases from primary breast carcinomas a clinicopathologic study of 3 autopsy cases REPORT OF CASES case 1. Arch. Pathol. Lab. Med. 128, 1418–1423 (1418).
Simone, C., Murphy, M., Shifrin, R., Toro, T. Z. & Reisman, D. Rapid liver enlargement and hepatic failure secondary to radiographic occult tumor invasion: two case reports and review of the literature. J. Med. Case Rep. 6, 402 (2012).
Deodhar, K., Munot, S., Rojekar, A. & Vaideeswar, P. Hepatic diffuse intra-sinusoidal metastases of pulmonary small-cell carcinoma. J. Postgrad. Med. 58, 230 (2012).
doi: 10.4103/0022-3859.101654
pubmed: 23023366
Galjart, B. et al. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Angiogenesis 1, 355–368 (2019).
doi: 10.1007/s10456-019-09661-5
Bohlok, A. et al. Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients. NPJ Breast Cancer 6, 64 (2020).
Cremolini, C. et al. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. Br. J. Cancer 118, 955–965 (2018).
Nierop, P. M. H. et al. Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns. Clin. Exp. Metastasis 36, 109–118 (2019).
doi: 10.1007/s10585-019-09960-7
pubmed: 30843120
pmcid: 6445820
Temido M. J. et al. Prognostic factors after hepatectomy for gastric adenocarcinoma liver metastases: desmoplastic growth pattern as the key to improved overall survival. Cancer Manag Res. 12, 11689–11699 (2020).
Vles, M. J. D. et al. Local tumour control after radiofrequency or microwave ablation for colorectal liver metastases in relation to histopathological growth patterns. HPB 24, 1443–1452 (2022).
doi: 10.1016/j.hpb.2022.01.010
pubmed: 35144863
Barnhill, R. et al. Replacement and desmoplastic histopathological growth patterns: a pilot study of prediction of outcome in patients with uveal melanoma liver metastases. J. Pathol. Clin. Res Oct. 4, 227–240 (2018).
doi: 10.1002/cjp2.105
Latacz, E. et al. Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. Br. J. Cancer 127, 988–1013 (2022).
doi: 10.1038/s41416-022-01859-7
pubmed: 35650276
pmcid: 9470557
Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 26, 259–2571 (2014).
Van Dam, P. J. et al. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br. J. Cancer 117, 1427–1441 (2017).
doi: 10.1038/bjc.2017.334
pubmed: 28982110
pmcid: 5680474
Wei, S. et al. Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy. Eur. J. Radiol. 142, 109863 (2021).
Mentha, G. et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br. J. Surg. 96, 95–103 (2006).
doi: 10.1002/bjs.6436
Rubbia-Brandt, L. et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann. Oncol. 18, 299–304 (2007).
doi: 10.1093/annonc/mdl386
pubmed: 17060484
Starmans, M. P. A. et al. Distinguishing pure histopathological growth patterns of colorectal liver metastases on CT using deep learning and radiomics: a pilot study. Clin. Exp. Metastasis 38, 483–494 (2021).
Cheng, J. et al. Prediction of histopathologic growth patterns of colorectal liver metastases with a noninvasive imaging method. Ann. Surg. Oncol. 26, 4587–4598 (2019).
doi: 10.1245/s10434-019-07910-x
pubmed: 31605342
Han, Y. et al. Identification of predominant histopathological growth patterns of colorectal liver metastasis by multi-habitat and multi-sequence based radiomics analysis. Front. Oncol. 10, 1363 (2020).
doi: 10.3389/fonc.2020.01363
pubmed: 32923388
pmcid: 7456817